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Acetazolamide arterial spin labeling to estimate cerebrovascular reserve 
in Moyamoya disease and syndrome 
 
We thank Dr. Mugikura and colleagues for their interest.  We agree with them 
that, like any medical intervention, acetazolamide administration is associated 
with risk, which must be interpreted relative to benefit. However, it is important 
to point out that this risk is small. Mugikura et al. in a prior letter (1) cite 
Japanese literature suggesting that acetazolamide was related to 6 fatalities 
in 400,000 to 600,000 administrations (0.001 -0.0015%) (2, 3). For reference, 
the estimated lifetime-adjusted cancer risk from radiation administered during 
a brain single photon emission tomography (SPECT) examination is at least 
100 times greater (4). The only study examining acetazolamide risk in English 
reported no adverse events in > 1000 studies (5). A more recent study 
examining MR diffusion changes following acetazolamide in a small cohort of 
Moyamoya patients could not detect any deleterious effects (6). 
 
In Moyamoya, the most common surgical treatment is external carotid – 
internal carotid (EC-IC) bypass, a complex procedure with non-negligible risk. 
Cerebrovascular reserve (CVR) assessment might inform on the optimal 
timing for surgery (7–9). In this context, where a low-risk diagnostic test 
identifies patients who may benefit from a higher risk surgical intervention, the 
risk–benefit ratio is likely justified. If CVR studies are performed, our article 
highlights that using arterial spin labeling (ASL) MRI instead of SPECT and 
PET will reduce cancer risk by avoiding the need for radioactivity. 
 
Alternative approaches to acetazolamide for CVR are currently being 
evaluated. These include breath-holding and carbon dioxide inhalation, and 
have frequently used blood oxygenation-level dependent (BOLD) as a 
surrogate CVR marker (10, 11). These approaches can be hard to implement 
and require patient compliance levels not necessary for acetazolamide 
studies.  Finally, the authors suggest indirectly assessing CVR using contrast-
perfusion MRI or the ‘ivy sign’ on fluid-attenuated inversion recovery (FLAIR). 
While interesting, this has limitations. We suggest considering ASL instead of 
GD enhanced MR perfusion, which might avoid the need of repetitive contrast 
injections. Evaluating the ‘ivy sign’ does not require contrast, but is qualitative 
and has not been directly compared to CVR.  These alternatives to 
acetazolamide CVR testing hold promise, but must still be validated in larger 
cohorts. 
 
References 
1. Mugikura S, Fujimura M, & Takahashi S. (2016). Implications of Off-
Label Use of Acetazolamide in the Management of Moyamoya Disease 
in Japan. (279(2)). Departments of Diagnostic Radiology * and. 
Neurosurgery, † Graduate School of Medicine, Tohoku University, 1-1 
Seiryo-machi, Aoba-ku, Sendai, Japan 980-8574. Departments of 
Diagnostic Radiology * and. 
2. Emergency warnings of the serious adverse effects of intravenous 
acetazolamide (diamox) administration [in Japanese]. (Japan Stroke 
Society, Japan Neurosurgical Society, Japanese Society of Neurology, 
and Japanese Society of Nuclear Medicine). Available from: 
https://www.neurology-jp.org/news/pdf/news_20140618_01_01.pdf. 
3. Guideline of the adequate use of intravenous acetazolamide 
administration [in Japanese]. Joint Committee on the Adequate Use of 
Intravenous Acetazolamide (diamox) Administration (Japan Stroke 
Society, Japan Neurosurgical Society, Japanese Society of Neurology, 
and Japanese Society of Nuclear Medicine). Available from: http://www. 
jsts.gr.jp/img/acetazolamide.pdf. 
4. Brix G, Nekolla EA, Borowski M et al. Radiation risk and protection of 
patients in clinical SPECT/CT. Eur J Nucl Med Mol Imaging 2014; 41 
Suppl 1S125-36. 
5. Piepgras A, Schmiedek P, Leinsinger G et al. A simple test to assess 
cerebrovascular reserve capacity using transcranial Doppler sonography 
and acetazolamide. Stroke 1990; 21(9):-1306-1311. 
6. Federau C, Christensen S, Zun Z et al. Cerebral blood flow, transit time, 
and apparent diffusion coefficient in moyamoya disease before and after 
acetazolamide. Neuroradiology 2017; 59(1):-5-12. 
7. Conklin J, Fierstra J, Crawley AP et al. Impaired cerebrovascular 
reactivity with steal phenomenon is associated with increased diffusion in 
white matter of patients with Moyamoya disease. Stroke 2010; 41(8):-
1610-1616. 
8. Kang KH, Kim HS, & Kim SY. Quantitative cerebrovascular reserve 
measured by acetazolamide-challenged dynamic CT perfusion in 
ischemic adult Moyamoya disease: initial experience with angiographic 
correlation. AJNR Am J Neuroradiol 2008; 29(8):-1487-1493. 
9. Antonucci MU, Burns TC, Pulling TM et al. Acute Preoperative Infarcts 
and Poor Cerebrovascular Reserve Are Independent Risk Factors for 
Severe Ischemic Complications following Direct Extracranial-Intracranial 
Bypass for Moyamoya Disease. AJNR Am J Neuroradiol 2016; 37(2):-
228-235. 
10. Pellaton A, Bijlenga P, Bouchez L et al. CO2BOLD assessment of 
moyamoya syndrome: Validation with single photon emission computed 
tomography and positron emission tomography imaging. World J Radiol 
2016; 8(11):-887-894. 
11. Su P, Mao D, Liu P et al. Multiparametric estimation of brain 
hemodynamics with MR fingerprinting ASL. Magn Reson Med 2016;  
 
